BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3163271)

  • 1. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
    Vilpo JA; Vilpo LM
    Cancer Res; 1988 Jun; 48(11):3117-22. PubMed ID: 3163271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S; Bhalla K; Rauscher F; Cadman E
    Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
    Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
    Ross DD; Chen SR; Cuddy DP
    Cancer Res; 1990 May; 50(9):2658-66. PubMed ID: 2328491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
    Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
    Ross DD; Akman SA; Joneckis CC; Yang E; Bachur NR
    Cancer Res; 1984 Apr; 44(4):1530-5. PubMed ID: 6584206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB; Tong WP; Chou TC
    Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
    Suzuki H; Kim SH; Tanara M; Okazaki K; Okabe T; Wu RT; Tanaka N
    Cancer Res; 1987 Feb; 47(3):713-7. PubMed ID: 3467840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM; Momparler RL
    Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S; Goto N; Nakamura T; Ueda T
    Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H; Drewinko B
    Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
    Spriggs D; Robbins G; Ohno Y; Kufe D
    Cancer Res; 1987 Dec; 47(24 Pt 1):6532-6. PubMed ID: 3479246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
    Ross DD; Joneckis CC; Song TH; Wu RK
    Cancer Res; 1988 Feb; 48(3):517-21. PubMed ID: 3335018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
    Tanaka M; Kimura K; Yoshida S
    Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
    Chan TC
    Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.